✦ LIBER ✦

Economic impact of extended treatment with peginterferon α-2a and ribavirin for slow hepatitis C virologic responders

✍ Scribed by J. Nakamura; S.-I. Toyabe; Y. Aoyagi; K. Akazawa

Book ID: 108886096
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 112 KB
Volume: 15
Category: Article
ISSN: 1352-0504
DOI: 10.1111/j.1365-2893.2007.00943.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Peginterferon Alfa-2b or Alfa-2a with Ri

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

✍ McHutchison, John G.; Lawitz, Eric J.; Shiffman, Mitchell L.; Muir, Andrew J.; G 📂 Article 📅 2009 🏛 Massachusetts Medical Society 🌐 English ⚖ 266 KB

Plasma ribavirin concentrations during t

Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon α-2b and ribavirin combination after liver transplantation

✍ J. Dumortier; E. Ducos; J.-Y. Scoazec; P. Chevallier; O. Boillot; M.-C. Gagnieu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

Clinical trial: extended treatment durat

Clinical trial: extended treatment duration of peginterferon-alpha2b plus ribavirin for 72 and 96 weeks in hepatitis C genotype 1-infected late responders

✍ M. NAGAKI; M. SHIMIZU; J. I. SUGIHARA; E. TOMITA; C. SANO; T. NAIKI; K. KIMURA; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 214 KB

Extending combination therapy with pegin

Extending combination therapy with peginterferon alfa-2b plus ribavirin for genotype 1 chronic hepatitis C late responders: A report of 9 cases

✍ Maria Buti; Auristela Valdés; Francisco Sánchez-Avila; Rafael Esteban; Yoav Luri 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 50 KB

Peginterferon α-2a (40 KD) plus ribaviri

Peginterferon α-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients

✍ Makoto Kuboki; Shiro Iino; Tadao Okuno; Masao Omata; Kendo Kiyosawa; Hiromitsu K 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB

Randomized trial of peginterferon alfa-2

Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response

✍ Maria Buti; Yoav Lurie; Natalia G. Zakharova; Natalia P. Blokhina; Andrzej Horba 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 197 KB 👁 2 views

The benefit of extending treatment duration with peginterferon (PEG-IFN) and ribavirin (RBV) from 48 weeks to 72 weeks for patients with chronic hepatitis C genotype 1 infection has not been well established. In this prospective, international, open-label, randomized, multicenter study, 1,428 treatm